---
layout: default
title: Amlodipina
parent: 僅模型預測 (L5)
nav_order: 29
evidence_level: L5
indication_count: 0
---

# Amlodipina
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# AMLODIPINA: Drug Repurposing Evaluation Report

## One-Sentence Summary

Amlodipina (amlodipine) is a well-known dihydropyridine calcium channel blocker widely used for hypertension and angina pectoris. The TxGNN model has **not generated any predicted new indications** for this drug at this time. Insufficient data is available in the current evidence pack to proceed with a repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|------|
| Drug (INN) | Amlodipina (Amlodipine) |
| DrugBank ID | Not available |
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | **None** — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No predictions, no supporting studies) |
| Italy Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

There is **no TxGNN prediction to evaluate** for Amlodipina at this time. The `predicted_indications` array in the evidence pack is empty, meaning the model either did not process this drug or did not identify any repurposing candidates above its confidence threshold.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on widely known pharmacological information, amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It is predominantly used for the treatment of hypertension and chronic stable/vasospastic angina. Without a TxGNN prediction, no mechanism-to-disease bridging analysis can be performed.

It is recommended that the drug name mapping be verified (e.g., confirming that "AMLODIPINA" correctly maps to the knowledge graph entity for amlodipine) and that the TxGNN pipeline be re-run before drawing any conclusions.

---

## Clinical Trial Evidence

Currently no predicted indication exists, therefore no related clinical trials have been retrieved.

---

## Literature Evidence

Currently no predicted indication exists, therefore no related literature has been retrieved.

---

## Italy Market Information

Amlodipina has **0 authorizations** recorded in the evidence pack. The market status is listed as "未上市" (Not marketed).

> **Note:** This may reflect a data retrieval issue rather than actual market absence. Amlodipine is a globally widely-used antihypertensive drug and is expected to have authorizations in Italy under various brand names (e.g., Norvasc). It is recommended to verify the AIFA database query using alternative search terms (e.g., "AMLODIPINE", "AMLODIPINO", or brand names).

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> All safety data fields (key warnings, contraindications, drug interactions) returned as data gaps. No drug-drug interactions were found in the DDI query. Before any repurposing evaluation can proceed, the package insert must be obtained and parsed.

---

## Data Gaps Summary

The following critical data gaps were identified and must be resolved before proceeding:

| Gap ID | Item | Severity | Impact | Recommended Remediation |
|--------|------|----------|--------|------------------------|
| DG001 | Package insert warnings / contraindications | **Blocking** | Cannot enter S1 safety screening | Download and parse package insert PDF from regulatory authority website |
| DG002 | Mechanism of Action (MOA) | High | Affects mechanism–indication relevance analysis | Query DrugBank API |
| — | DrugBank ID | High | Cannot link to structured pharmacological data | Verify mapping for "AMLODIPINA" in DrugBank |
| — | Original indications | High | Cannot establish baseline for repurposing rationale | Extract from authorization records or DrugBank |
| — | TxGNN predictions | **Blocking** | No repurposing candidates to evaluate | Verify KG entity mapping and re-run prediction pipeline |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack contains no TxGNN predictions for Amlodipina, and critical data fields (MOA, original indications, safety profile, regulatory authorizations) are all missing or empty. There is no repurposing hypothesis to evaluate at this stage.

**To proceed, the following is needed:**
- **Verify drug name mapping**: Confirm that "AMLODIPINA" correctly resolves to the amlodipine entity in the TxGNN knowledge graph; try alternative spellings (AMLODIPINE, DB00381)
- **Re-run TxGNN prediction pipeline** after confirming the entity mapping
- **Obtain DrugBank ID and MOA data** via DrugBank API query
- **Re-query the Italian (AIFA) regulatory database** with alternative search terms to retrieve authorization records
- **Obtain and parse the package insert** to populate safety fields (warnings, contraindications, DDI)
- **Re-generate the evidence pack** once the above gaps are filled, then re-evaluate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

